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The Sirtuins are a family of orthologues of yeast Sir2 found in a wide range of organisms from bacteria to man. They display a
high degree of conservation between species, in both sequence and function, indicative of their key biochemical roles. Sirtuins are
heavily implicated in cell cycle, cell division, transcription regulation, andmetabolism, which places the various family members at
critical junctures in cellular metabolism. Typically, Sirtuins have been implicated in the preservation of genomic stability and in the
prolongation of lifespan though many of their target interactions remain unknown. Sirtuins play key roles in tumourigenesis, as
some have tumour-suppressor functions and others influence tumours through their control of themetabolic state of the cell. Their
links to ageing have also highlighted involvement in various age-related and degenerative diseases. Here, we discuss the current
understanding of the role of Sirtuins in age-related diseases while taking a closer look at their roles and functions in maintaining
genomic stability and their influence on telomerase and telomere function.
1. Sirtuins
Sirtuins are a highly conserved family of proteins found in all
organisms from yeast to mammals. All are orthologues of the
yeast protein, silent information regulator 2 (Sir2) [1] and
their primary targets are acetylated lysines of various pep-
tides and proteins, including histones. Along with sequence
homology, they also share functional similarities although
the functions performed inmammals aremore complex than
in yeast, as reflected in the number of distinct orthologous
forms. These play key roles in cellular stress and ageing, and
as such, their function has been linked to diseases associated
with ageing, including Alzheimer’s [2], Parkinson’s Disease
[3], cancer [4], type II diabetes [5], and atherosclerosis [6].
Every member of the family contains a highly conserved
core domain consisting of a NAD+-binding site and a cat-
alytic domain [7]. Sirtuin function is tied to cellular energy
production through nicotinamide adenine dinucleotide-
(NAD+-) dependent deacetylation reactions, as well as o-
ADP ribosylation, in response to changes in the cellular
NAD+/NADPH ratio. Sirtuins appear to be involved in the
extension of life span and health promotion in several species
including yeast, nematodes and flies [8]. Pertinent to this is
the observation that Sirtuins can be activated through caloric
restriction, stress, or by pharmacological agents [9]. Sirtuins
have a pivotal role in the expansion of lifespan in lower
organisms via caloric restriction [10–15]. This phenomenon
is also believed to occur in higher mammals, and ongoing
studies in monkey models have demonstrated promising
results in proving this connection [16]. Additionally, some
small-scale studies with centigenarians have demonstrated
that allelic variants of some Sirtuin genes are linked to
longevity in humans [17–19]. Despite this, the involvement
of Sirtuins in enhanced human health and lifespan is still
the subject of great debate. There is, however, increasing
corroborative evidence of their links to cancer processes,
genomic instability and other diseases of ageing.
Central to such associations is the observation that
Sirtuin activity is directly correlated with the metabolic state
of the cell [20]. Sirtuins act as substrate-specific type III
protein lysine deacetylases, in contrast to the classic deacety-
lases, which facilitates a link between cell metabolism and
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Figure 1: Protein deacetylation by Sirtuins. Sirtuins deacetylate lysine (K) residues of target proteins using cofactor—Nicotinamide-adenine-
dinucleotide (NAD+) and releasing Nicotinamide (NAM). 2′-O-acetyl-ADP ribose is generated as a result of transfer of the acetyl group of
K onto ADP-ribose residue. Deacetylation is inhibited by NAM, which can also reverse the reaction to reproduce NAD+.
control of transcription. Briefly, the deacetylation involves a
unique enzymatic NAD+-dependent reaction which begins
with amide cleavage from NAD+ leading to the forma-
tion of Nicotinamide (NAM) and a covalent ADP-ribose
peptide-imidate intermediate (ADPR). This intermediate is
transformed to O-acetyl-ADP-ribose and the deacetylated
protein is released from the complex (Figure 1, [21]). Due
to the reliance of Sirtuin deacetylation activity on NAD+,
it is hardly surprising that evidence suggesting NAD+ and
NAD+ generating pathways are directly involved in the
regulation of Sirtuin activity is mounting rapidly. This is
supported by the observation that the Nicotinamide (NAM)
product site can be occupied in the presence of substrates
and reaction intermediates [22, 23]. Bound NAM is able
to inhibit the enzymatic activities of Sirtuins and can, in
some cases, reverse the reaction, thus regeneratingNAD+ and
the acetylated substrate. Sirtuins, together with other NAD+
consumers (ADP-ribosyltransferases and cAMP ribose syn-
thetase), have also been implicated in the salvage/elimination
of NAM, thus playing a vital role in the homeostatic
maintenance of NAD+ metabolism [7, 24].
In humans, seven Sirtuins have been identified (Sirt1–
7) [25, 26], all with unique characteristics, functions, and
localisations (Table 1).
Sirt1, Sirt6, and Sirt7 are localised mainly in the nucleus,
whereas Sirtuins 3–5 are found mainly in the mitochondria
[27]. Conversely, Sirt2 has a predominantly cytoplasmic
localisation [28, 29].
The Sirtuins contain nuclear localisation signals (NLSs)
as well as nuclear export signals (NESs) and their intracellu-
lar localisation is determined by cell/tissue type and phys-
iological conditions. Sirt6 and Sirt7 contain a single NLS,
while Sirt1 contains 2 NLS and 2 NES domains [29, 30]. The
presence of an N-terminal mitochondrial targeting sequence
ensures Sirt3–5 localisation within the mitochondrial matrix
[31, 32], whereupon the signal sequence is cleaved, activating
the enzymatic function of the proteins. Interestingly, it
has been recently suggested that under specific conditions
(stress), Sirt3 can translocate from mitochondria to the
nucleus [33, 34].
Sirtuins are actively involved in the regulation of gene
expression, principally due to their histone deacetylase activ-
ity and the consequential ability to influence the activity of a
wide range of transcription factors. It has been shown that all
Sirtuins, with the exception of Sirt4 and Sirt7, have histone
deacetylase activity (HDAC). Sirt1 can aﬀect core histones
(H1, H2, H3, and H4), but it preferentially deacetylates
H3 (K9, K14 and K56 residues), H4 (K16) and H1 (K26)
[35–37]. The specific deacetylation of lysine residues at
H3K9/H4K16 and H1K26 by Sirt1 has been linked to gene
silencing and chromatin remodelling. Additionally, histone
deacetylation can facilitate the methylation of histones, for
example, di/tri-methylation of H3 on the K9 residue and H4
on the K20 residue. These modifications have been linked
to global transcriptional repression and are characteristic
for facultative heterochromatin [38]. This reaction can be
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Table 1: The mammalian Sirtuins.
Enzymatic activity Localisation Substrates/targets Function
SIRT1 Deacetylase Nuclear/cytoplamic
p53, FOXO, NFκB, MyoD,
Ku70, LXR, PPARγ, p300,
Tat, PCAF, ERα, AR,
SMAD7, PCAF, p73, Sox9,
HES1, PGC1α, HEY2,
NcoR/SMRT, E2F1,
RelA/p65
Glucose metabolism,
fatty-acid and cholesterol
metabolism,
diﬀerentiation, insulin
secretion, and
neuroprotection
SIRT2 Deacetylase Nuclear/cytoplamic α-tubulin, FOXO
Cell-cycle control, tubulin
deacetylation
SIRT3 Deacetylase AceCS2, GDH complex1
ATP production, regulation
of mitochondrial proteins
deacetylation, and
fatty-acid oxidation
Mitochondrial
SIRT4 ADP-ribosylotransferase GDH, IDE, ANT Insulin secretion
SIRT5 Deacetylase CPS1 Urea cycle
SIRT6
Deacetylase
ADP-ribosylotransferase
Nuclear
NFκB, Hif1α, helicase,
DNA polymeraseβ
Telomeres and telomeric
functions, DNA repair
SIRT7 Deacetylase Nuclear
RNA polymerase type I,
E1A, SMAD6
RNA polymerase I
transcription
further enhanced by Sirtuins; for example, H3K9 methyla-
tion is enhanced by Sirt1. Sirt1 binds to the histone methyl-
transferase Suv39H1 (suppressor of variegation 3–9 homolog
1) and facilitates binding of this protein to chromatin. Sirt1
is then activated by deacetylation of Suv39H1 [36, 39].
There are additional regulation mechanisms involved in the
chromatin silencing mediated by Sirt1-Suv39H1 complex,
it has recently been shown that deleted in breast cancer 1
(DBC1), not only inhibits both Sirt1 and Suv39H1 activity,
but also disrupts the interaction between these twomolecules
leading to the increased methylation of H3K9 [40]. The
other interesting aspect of Sirt1 involvement in the epigenetic
regulation of gene expression is its association with aberrant
expression of the methylated genes that can be facilitated by
its interaction with Dnmt3b [41] or Dmnt1 [42]. Overall,
the ability of Sirt1 to remodel chromatin, together with the
ability of this enzyme to deacetylate and/or interact with a
broad range of transcription factors (i.e, p300, NFκB, FOXO,
E2F1, and Smad7 (Table 1)) suggest that Sirt1 may be a
major player in the regulation of organism homeostasis,
stress responses, endocrine signalling, and cell metabolism.
Acetylated lysine residues on Histone 4 (H4K16) and
Histone H3 (H3K9) are targets for Sirt2 deacetylation when
the nuclear envelope disassembles during the mitotic process
[43]. This makes Sirt2 a regulator of the cell cycle, involved
in the promotion of chromatin condensation. Similarly,
Sirt3 deacetylates H4K16 and H3K9 in vitro although the
importance of this process under in vivo conditions remains
somewhat controversial [34].
Finally, Sirt6 deacetylates H3K9 at telomeres, indicating
that this particular molecule may be a modulator of cellular
senescence and ageing induced chromosomal abnormalities
[44].
Sirtuins are also involved in the regulation of RNA
Polymerase II transcribed genes although their involvement
in the formation of the transcription initiation complex has
not been proven to date [45]. Interestingly, Sirtuins aﬀect
transcription of ribosomal RNA also. Sirt1 and Sirt7 have
opposing eﬀects on rRNA transcription; Sirt1 deacetylates
TATA box-binding protein associated factor (TAFI68) lead-
ing to the inhibition of Polymerase I [46], while Sirt7 directly
binds to polymerase I and induces enzyme activity [47].
A search for Sirtuin-binding sites revealed many putative
targets. However, all of these targets follow on a common
theme in Sirtuin function, namely, cellular stress responses
[48]. These incorporate cell death responses, senescence,
stress-related transcription regulation, cell-cycle control,
cell metabolism, genomic stability and formation, and
maintenance and control of telomeric function (Table 1).
These activities for Sirtuins reinforce the link between key
features of cellular bioage and disease, centred on telomere
stability and cellular lifespan. Extrapolating Sirtuin activity
to longevity, already established in lower organisms is thus
intuitive for higher animals though it remains unproven. The
increasing evidence for Sirtuin involvement in age related
diseases is a key link to their function in the control of the cell
lifespan and genomic stability [49–51]. This involvement in
age-related disease further supports the link between Sirtuin
function and longevity, possibly making Sirtuins the key to
unlocking the causes and treatments for many age related
diseases.
2. Sirtuins and Genomic Instability
The involvement of Sirtuin function in disease is typified
by Sirt1, which is rapidly emerging as a tumour keystone,
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providing both tumour suppressor and tumour promoter
functionality [52]. Sirt1 has been shown to be overexpressed
in several cancers, including prostate [53], acute myeloid
leukaemia [54], colon cancer [55], and some nonmelanoma
skin cancers [56]. Sirt1 has also been observed to be repressed
in many other cancers, including glioblastoma, bladder,
ovarian, and prostate cancers [57]. This duality of purpose
indicates the pivotal role this Sirtuin exerts in the cell.
Overexpression of Sirt1 can lead to deacetylation of p53 [58,
59] and reduction of many tumour suppressor genes, thus
promoting genomic instability by reducing the cell’s ability
to respond to DNA damage and stress. Conversely, it can also
deacetylate B-catenin causing the oncogenic form of this pro-
tein to translocate to the cytoplasm, thus reducing the growth
of tumours [60]. More recently, Oberdoerﬀer et al. have
demonstrated that redistribution of Sirt1 in a mouse model
of genomic instability results in improved survival rates and
transcription profiles similar to those found in the ageing
process, particularly involved in repairing DNA breaks and
other forms of genomic instability [61]. Further investigation
into Sirt1 involvement in genomic instability has been ham-
pered by an inability to produce a viable null model, as Sirt1
knockout mice die during the mid-gestation stage although
it was determined that these mice showed histone mod-
ifications and impaired DNA-damage repair. Additionally,
Sirt1 and p53 heterozygotes showed an increase in tumour
formation in multiple tissues, a phenotype that could be at
least partially rescued by activation of Sirt1 using Resveratrol
[57]. It is still undetermined whether this Sirtuin acts as a
tumour keystone with suppressor or promoter functions.
Sirt2, which acts as a G2 checkpoint mitotic regulator,
appears to have a similar dichotomous role in both the
formation and prevention of gliomas [62]. Increased expres-
sion of Sirt2 has been linked to a prolonged cell-cycle, with
severe delays in cell cycle progression, suggesting a tumour
suppressor role [63]. Furthermore, its role as a mitotic check-
point protein helps prevent chromosome instability and
the development of hyperploidy [64]. Downregulation of
Sirt2 has been shown to interfere with cell cycle progression
and in some cases can induce cell-cycle arrest [65], while
overexpression has been shown to cause a prolongation of the
mitotic phase of the cell cycle [63] resulting in multinucle-
ated cells [28, 65]. The induction of multiploidy phenotypes
indicates that Sirt2 plays a role in chromosomal stability
by controlling the cell division associated separation of
recently replicated chromosomes. Sirt2 directly deacetylates
α-tubulin, providing it with a further mechanism for the
control over mitosis and its ability to ensure single ploidy
cells [64], thus ensuring genomic stability during mitosis.
Sirt3 may play a role in mitochondrial redox regulation
[27] though data on its role is equivocal. Two independent
studies have demonstrated that Sirt3 null mice have no
associated phenotype, with normal development and fertility
[66, 67]. Conversely, another Sirt3 null model, using mouse
embryonic fibroblasts, has demonstrated abnormal mito-
chondrial function, including an increase in stress-induced
ROS and genomic instability [68]. In this model, expression
of a single oncogene (c-myc or ras) was suﬃcient for neoplas-
tic transformation of the cells, which could be reversed by
introducing superoxide dismutase to counteract the increase
in ROS. It has now been shown, by the same group, that
this eﬀect is dependent upon deacetylation of mnSOD [69].
Mice with Sirt3 knockouts also developed oestrogen receptor
(ER)+ and Progesterone receptor (PR)+ mammary tumours,
suggesting that Sirt3 is a mitochondrially localised tumour
suppressor. However, there is still some debate over the
localisation of Sirt3, with the majority of studies claiming
that Sirt3 is exclusively mitochondrial [70, 71]. Notably, two
distinct forms (long and short) of Sirt3 have been reported
[72–74] with the short version lacking a mitochondrial
localisation signal peptide, indicating it may be localised else-
where. This may account for the equivocal reports that Sirt3
can be localised to the nucleus. There are also reports that
suggest Sirt3 translocates to the nucleus upon overexpression
of Sirt5 or oxidative challenge to the cell [33, 34]. These
reports did not investigate whether this was accomplished by
translocation of Sirt3 from mitochondria to the nucleus, de
novo synthesis, or expression of the short version of Sirt3.
Sirt4 shows no discernable NAD+-dependent deacetylase
activity in vitro [75, 76], confirmed by a lack of mitochon-
drial protein acetylation variation in a null mouse model
[67]. Like Sirt3 null mice, Sirt4 null mice demonstrate an
overtly normal phenotype [50]. Sirt4 is associated with
insulin secretion by pancreatic β-cells, which may link
it to type II diabetes, an age-related disorder. There is
no direct evidence to date, however, that Sirt4 has any
direct aﬀect on genomic stability, through either over- or
underexpression. Recently it has been suggested that Sirt3
and Sirt4 activities are antiapoptotic in response to DNA
damage when extremely low levels of NAD+ are present [77].
Sirt5 localises to the mitochondrial matrix, where its N-
terminus is cleaved. Sirt5 appears to operate exclusively in
the mitochondria and one of its major targets is carbamoyl
phosphate synthase 1 (CPS1) [78], which is responsible for
converting ammonia to urea. It also regulates the entry of
ammonia into the urea cycle. Therefore, it would appear
that the major function of Sirt5 in vivo is to enhance the
body’s reaction to the breakdown of amino acids during
calorie restriction via CPS1 and Cytochrome C [79, 80].
Very little else is known about the function of Sirt5 other
than that it has been demonstrated that Sirt5 plays a role
in the localisation of Sirt3 [34]. Sirt3 is ordinarily present
in the mitochondria; however, overexpression of Sirt5 causes
Sirt3 to localise to the nucleus this phenomenon has also
been shown as part of the cell stress response [33]. Whether
this is due to increased expression of Sirt3 Short has yet to
be established. This indicates that Sirt5 may contribute, in
part, to the cellular response to stress, or that it is produced
as a result of the stress response. Given the dependence
of Sirtuins on NAD+ for their action, it is feasible that
Sirt5 is part of the sensing apparatus to initiate the stress
response and would then activate it’s deacetylation functions
to aﬀect other transcription factors, thus initiating the cell
wide stress reaction, which may include sending Sirt3 to
the nucleus. Therefore, Sirt5 may exert an influence over
genomic stability via the action of Sirt3.
The role of Sirt6 has been established as being a
key component of base excision repair (BER), as part of
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intra-cellular DNA-damage responses. Sirt6 directly sta-
bilises DNA-dependant protein kinase at the site of dsDNA
breaks, allowing the formation of the DNA repair complex
and the initiation of repairs [81]. Sirt6 also associates
directly with chromatin, demonstrated by its association
with chromatin enriched cellular fractions [82]. Sirt6 has
also been shown to localise to the promoter regions of
NF-κB activated proteins, whereupon it deacetylates the
associated H3 histone at Lysine 9, thereby silencing the
recently activated genes [65]. Sirt6 deficiency is associated
with shortened lifespan and accelerated ageing phenotypes.
In fact, mice with Sirt6 knockouts have been shown to
have a progeroid phenotype, with extreme hypoglycaemia
and are unable to survive beyond 4 weeks. The lethal
hypoglycaemia observed in Sirt6 deficient mice is a direct
result of its H3K9 deacetylase function which controls the
expression of glycolytic genes [83]. Furthermore, knockout
mice demonstrate a very high level of genomic instability and
hypersensitivity to DNA damage [82, 84], confirming Sirt6’s
key role in DNA damage repair and also demonstrating
its close relationship with the original Sir protein in yeast,
Sir2. It was also noted that the increased sensitivity to DNA
damage did not appear to be a function of impaired cell-
cycle checkpoints, nor the dsDNA break repair mechanism.
Deletion of Sirt6 results in chromosomal abnormalities
including breaks and fusions, as well as a breakdown in
BER, a phenotype that can be rescued by introduction of a
fragment of Polymerase β (Polb), which has been determined
as a target for Sirt6 [85]. The deacetylation of histones by
Sirt6 is likely to have a stabilising eﬀect on the genome, for
example, H3K56 [86] although a direct link has yet to be
established.
Sirt7 directly interacts with RNA polymerase I (Pol
I) and histones, giving a direct link between this Sirtuin
and genomic stability [87]. This link is demonstrated by
increasing Sirt7 levels directly increasing Pol I function and
inhibition of Sirt7 leading to decreased Pol I activity [47].
Complete depletion of Sirt7 results in cell death, after a com-
plete halt to cell proliferation; it is believed that this direct
linkage allows Sirt7 to regulate Pol I function with regard to
NAD+ levels, tying it to cell metabolism and energy levels
in keeping with the original postulate of Shiels and Davies
(2003) [48]. They argue that cellular responses to stress and
damage centre on how much damage has been accrued, how
much energy the cell needs to eﬀect any repair, and how
much fuel it must burn to achieve this. If the damage is too
great; the cell will eﬀect death, however, if the damage is not
critical, then cellular energy metabolism is regulated to allow
repair, and ribosome biogenesis is modulated to facilitate this
[48, 88].
All cells have an in built mitotic clock associated with
telomeres [89], this clock is continually reset in germ line
cells by telomerase, and it also appears to bemodified, turned
oﬀ, or reset in cancer to allow tumours to grow unabated.
It has been well established that ageing is associated with
the degradation of telomeres, which ultimately leads to cell
senescence and apoptosis when the cell has reached the end
of its useful life [48]. The system of telomeric instability
associating with age is an essential checkpoint in the control
of life and disease, in particular cancer. Sirtuins are rapidly
emerging as the key link between ageing, disease, metabolism
and cellular stress.
3. Sirtuins and the Regulation of
Cellular Stress Responses
The intricate role Sirtuins play in the control of the
cell metabolism is mediated through their dependence on
NAD+; this control inextricably links their function with
the metabolic status of the cell. It also provides a sensing
platform for the response to cellular stress.
p53 tumour suppressor is involved in the regulation
of apoptosis and its reactivity is tightly regulated. Under
physiological condition, this molecule is maintained at very
low levels in the cells, but its expression is rapidly increased
in response to stress in order to fulfil its regulatory functions
[90]. It has been documented that p53 activity can be
modulated by SIRT1 in particular; overexpression of SIRT1
not only abrogated p53 dependent apoptosis in response to
oxidative stress, DNA damage, and ionizing radiation, but
also sensitised cells to apoptosis induced by these factors [58,
59]. Various studies have demonstrated that SIRT1 plays a
critical role in the regulation of both p53 dependent and p53
independent apoptosis in response to oxidative stress. This
regulation occurs via the deacetylation of p53 which leads
to its retention in the cytoplasm and enhances passage of
p53 into the mitochondria [91, 92]. The ability to modulate
p53 acetylation establishes SIRT1 in the inhibition of cell
senescence in response to oxidative stress. In this case, SIRT1
is recruited to the PML bodies and p53, where it blocks
p53-dependent transactivation; this phenomenon has been
observed in human endothelial cells, where Downregulation
of SIRT1 led to increased acetylation of p53 and development
of a premature senescence phenotype [93, 94]. In contrast to
SIRT1, SIRT2 overexpression promotes neurodegeneration
and aﬀects the ability of cells to recover after cellular stress,
mainly due to Downregulation of 14-3-3ζ [95, 96].
Another mechanism by which Sirt1 can regulate the
cellular response to stress is the ability of Sirt1 to regulate
members of the FOXO (Forkhead box class O) transcription
factor family. Sirtuin 1 deacetylates 3 members of FOXO
family, Foxo1, Foxo3a, and Foxo4 [97, 98]. Sirt1 regulation
of Foxo3a function in mammalian cells reduces apoptosis in
response to cellular stress, but also increases the expression
of genes involved in DNA repair and cell-cycle check points
[97]. SIRT1 activates Foxo1 and Foxo4 which are involved
in the promotion of cell-cycle arrest by induction of p27Kip1
and in enhancing cellular defences against oxidative stress
through the regulation of manganese superoxide dismutase,
catalase, and GADD45 (growth arrest and DNA damage
inducible α) [98, 99]. It has been demonstrated that
Sirt2 under oxidative stress deacetylates Foxo3a, and thus
enhances the expression of Foxo-regulated genes and reduces
ROS levels in cells [100]. Similarly to Sirt1, Sirt7 depletion
in mice leads to a specific phenotype, characterised by p53
hyperacetylation and lack of resistance to the oxidative or
genotoxic stress [101].
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4. Sirtuins, Telomeres, and Telomerase
TNFα has been shown to induce telomerase activity in lym-
phocytes [102], this proinflammatory cytokine is controlled
by NF-κB which in turn is influenced by Sirt1. Therefore,
Sirt1 has direct influence over TNFα activation of telomerase
activity. Whether this activation can be achieved in cells
other than lymphocytes or whether it can contribute to the
immortalisation of tumour cells has yet to be elucidated.
Inhibition of Sirt1 has also been associated with increased
telomerase activity in human cells [103].
Sirt2 is predominantly cytoplasmic and is unlikely to
play any role in telomere biology. Sirt3–5 are mitochondrial
and to date have no information linking them to telomeric
sites, telomerase, or mitotic division. However, Sirt6 is
absolutely essential for dsDNA repair, playing an active
role in the recruitment of other factors to the site of
dsDNA breaks [81]. Sirt6 also appears to be extremely
important in the maintenance of telomeres and telomeric
function. Recent studies have demonstrated that reduction
or removal of Sirt6 results in telomere dysfunction and
end-to-end chromosomal fusions. This absence of Sirt6 is
similar in symptoms to Werner’s syndrome, which is a
disease characterised by premature ageing. It is an extremely
rare, autosomal recessive disorder caused by a mutation in
the WRN gene encoding DNA helicase [44]. This results
in genomic instability and telomeric attrition, the process
by which this occurs is unknown. It is believed that Sirt6
is essential for proper telomere maintenance and function.
Sirt6-deficient cells have been shown to have an increased
susceptibility to genotoxic DNA damage resulting in the
accumulation of chromosomal abnormalities resulting in
genomic instability. Sirt6-deficient mice exhibit an accel-
erated ageing phenotype; however, the researchers were
unable to determine any cellular lifespan change [82].
In another study using Sirt6 null mice it was demon-
strated that these mice have a progeroid like syndrome,
profound hypoglycaemia, and premature death at around
the 4-week stage [50]. This appears to indicate that Sirt6
does, in fact, have a major impact on organismal lifespan
control.
Very little is known about Sirt7, and although it is
localised to the nucleolus, there has been no evidence
presented that suggests any involvement with telomere
function, formation, or stability.
5. The Association of Sirtuins with
Diseases of Ageing
Sirt1 is heavily implicated in several diseases associated with
ageing, as well as with ageing itself. This Sirtuin has been
shown to protect axons from damage in animal models of the
Wallerian degenerative disease (Parkinson’s disease) [104].
Furthermore, the use of resveratrol (a Sirt1 activator) in
models of Huntington’s disease shows that Sirt1 is able to
reduce cell death by inhibition of NF-κB signalling [105].
Alzheimer’s disease has also been linked to Sirt1 function
and calorie restriction in monkeys [106]. A recent study has
demonstrated that Sirt1 overexpression in the brain of mice
directly reduces β-Amyloid production and the formation of
plaques [107]. Another study demonstrated that induction
of Sirt1 function also reduced macular degeneration by
protecting retinal ganglial cells [108]. Furthermore, it has
been shown that Sirt1 has a direct influence on the pancreatic
β cell production of insulin. Along with Sirt3, altered
expression of these Sirtuins has been implicated in the
development of Type II Diabetes [8]; however, no links with
Type I diabetes have yet been established. This activity is
believed to occur through acetyl coenzyme A synthetase
(AceCS) upon which both Sirt1 and 3 act to produce acetate.
The production of acetate has been shown to be disrupted
in diabetes as well as in ageing. Sirt4 has also been shown to
be downregulated in pancreatic b cells in response to calorie
restriction implicating it in diabetes although no links have
yet been demonstrated.
Although Sirt2 is associated mainly with the brain,
there have been no links made between this Sirtuin and
neurodegenerative diseases. The limited amount of infor-
mation available on Sirt5 makes it very diﬃcult to make
any connections between this Sirtuin and diseases of ageing;
however, its heavy involvement in the mitochondria leads to
speculation that it may be related to metabolic disorders.
Sirt3 has been linked to overall longevity in humans,
although the studies conducted were small scale. The first
study linked a polymorphism in Sirt3 to increased longevity
in males [19], and the authors also determined that the
chromosomal location of Sirt3 is also home to four other
proteins associated with longevity (tyrosine hydroxylase,
proinsulin, IGF2, and HRAS1). A subsequent study con-
firmed this observation but went further to suggest that
decreased levels of Sirt3 was detrimental to longevity inmales
[17]. Furthermore, Lescai et al., (2009) [109] linked a Sirt3
SNP to longevity in centenarians from Italy, France, and
Germany. Recently, Sirt3 has been directly linked to age-
related hearing loss [110].
Sirt6 is heavily associated with DNA damage, telomeres,
and cancer. Another link to degenerative disease exists
with the association between Sirt6 and WRN which is
implicated in premature ageing likeWerner Syndrome [111].
Furthermore, Sirt6 actively represses genes associated with
age-related cellular senescence and it is, therefore, highly
likely that more associations will be discovered and that Sirt6
will become a key player and target in the research and
treatment of cancer and other age-related diseases. There
is also a suggestion that it may play a key role in the
maintenance of organ integrity particularly associated with
ageing [8]. Another key mediator in age-related diseases is
inflammation, which in this context is generally induced
by age-related increases in NF-κB activity. This activity
is directly opposed by both Sirt1 and Sirt6, where Sirt1
acts directly on the RelA subunit causing deacetylation
and reducing its action. Sirt6 is also sequestered to NF-κB
activated targets and shuts them down at the transcription
level. Thus, both Sirtuins may be active in age-related
inflammatory disorders. Although no direct causal links
between these Sirtuins and inflammatory disorders have
been made, the level of circumstantial evidence suggest that
formal demonstration may be a matter of time and research.
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Sirt1 and Sirt7 are associated with age-related cardiovas-
cular disease through their interactions with p53, Fox01 and
nitric oxide synthetase (NOS). Sirt1 has also been shown to
improve the regeneration of vascular endothelia and smooth
muscle cells [112].
6. Sirtuins and Cancer
Cancer is now established as a disease of ageing. Conse-
quently it was inevitable that Sirtuins would play a vital
role in tumourigenesis. The roles played by Sirtuins at key
points in the cell are also highly indicative of their roles in
modulating the aberrant survival and replication of tumour
cells. The most obvious involvement for Sirtuins in cancer
comes from Sirt1 and Sirt7 mediation of p53-function,
which is well established as a focal point in many cancers.
Sirt1 (and Sirt7) deacetylates p53 reducing its influence
over cell cycle control during stress and in response to
DNA damage. Thus overexpression of Sirt1 deactivates p53
and disrupts p53 dependent pathways and this results in a
large reduction in the cell’s ability to respond to stress and
DNA damage [58, 59]. This has lead to many researchers
describing Sirt1 as a tumour promoter, a suggestion that
has now been supported by several studies. These identify
increased levels of Sirt1 associated with various cancers
including prostate [53], AML [54], primary colon [55]
and several nonmalignant skin cancers [56]. Overexpression
studies resulted in lowered production and or action of
several key tumour suppressors including FOXO family
members [113], p73 [114], RB [115], and several others
[116–119]. However, the story for Sirt1 is not so simple.
Several studies have reported decreased levels in cancer, for
example glioma, bladder, prostate, and ovarian cancers [57].
Several studies have reinforced this connection demonstrat-
ing a reduced level of Sirt1 associated with tumourigenesis
[118, 120–122]. In fact, Sirt1 acts as a tumour keystone,
where its level and actionmaintain a fine and delicate balance
between suppression and promotion of oncogenesis. Based
on the available evidence, it is plausible that Sirt1 acts as a
suppressor and then a promoter (or vice versa) depending
on the stage and situation of tumourigenesis.
Control of cell-cycle progression by Sirt2 has been
shown to be essential in the prevention of tumours, as it is
suppressed in gliomas [62]. Sirt3 is the only mitochondrial
Sirtuin to have a demonstrated role in tumourigenesis to
date and its reduction in several cancers leads to an increase
in ROS which results in enhanced tumour growth [68].
Interestingly, Sirt5 overexpression has been implicated in a
study of pancreatic cancer [123].
The role of Sirt6 in controlling NF-κB function and DNA
damage repair also indicate a key role in tumourigenesis
although very little information is available on specific
correlations with cancer to date some studies have been
conducted which demonstrate a link through interaction
with GCIP in colon tumours [124]. Our group has previously
demonstrated that Sirtuins 3–7 are elevated in some forms
of breast cancer [49] and mRNA levels of Sirt7 have been
inversely correlated with the ability to undergo tumourige-
nesis in mouse cell lines [125]. Sirtuin influence and types of
Table 2: Cancers associated with Sirtuins and their proposed
mechanism of involvement.
Association with cancer
Sirt1
Acute myeloid leukemia, colon, nonmalignant skin,
bladder, prostate ovarian cancers, and
glioma—mediates p53 function
Sirt2 Glioma—control of cell cycle progression
Sirt3
Breast cancer—decrease in levels is associated with a
general increase in tumour growth due to increase in
ROI
Sirt4 Breast cancer—metabolic
Sirt5 Pancreatic, breast cancers—metabolic
Sirt6
Colon, breast cancers—mediates NFκB and GCIP
function
Sirt7 Breast cancer—mediates p53 function
cancer where associations have been shown are summarised
in Table 2.
An interesting link between Sirtuin levels and circadian
rhythm has also been reported [126]. This is noteworthy
given the understood disruption of circadian rhythm in
cancer [127]. This opens the possibility of the use of
chronotherapy using Sirtuin regulators at specific times to
target tumours [126].
It is obvious that the Sirtuins, in line with the function
of Sir2 in yeast, play critical roles in the maintenance of
the genome in all organisms. These vital roles have led
to speculation that these molecules are heavily involved in
two key areas, tumourigenesis and ageing. Further, evidence
for these proteins in such crucial roles is accumulating
at an accelerating rate. As this area of molecular science
consolidates and advances, the Sirtuin family of proteins
are gaining significance in human biology and disease. This
group show strong potential to become valuable predictive
and prognostic markers for disease and as therapeutic targets
for the management of a variety of cancer types and other
age-related diseases.
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